CGTX Stock CGTX is expected to report earnings to rise+9.26% to -25 cents per share on May 08

A.I.dvisor
at Tickeron.com
05/07/24
Loading...
CGTX - Cognition Therapeutics
Cognition Therapeutics Earnings Graph
Q1'24
Est.
$-0.25
Q4'23
Beat
by $0.05
Q3'23
Beat
by $0.02
Q2'23
Beat
by $0.02
Q1'23
Missed
by $0.03
The last earnings report on December 31 showed earnings per share of -27 cents, beating the estimate of -32 cents. P/B Ratio (3.272) is normal, around the industry mean (10.333). P/E Ratio (0.000) is within average values for comparable stocks, (113.052). CGTX's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.445). CGTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.000) is also within normal values, averaging (208.102). With 24.82K shares outstanding, the current market capitalization sits at 80.08M.
View a ticker or compare two or three
CGTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2500 Westchester Avenue
Phone
+1 412 481-2210
Employees
28
Web
https://www.cogrx.com